Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | PPARD | Q03181 | 6/20 | 0.38 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3197897 | 1.00 | TSHR (0.44) | TSHRLMNANFKB1PMP22BBOX1 | |
| Bromide SCHEMBL4897598 | 0.84 | BBOX1 (0.35) | LMNABBOX1SLC22A6 | |
| Bromide SCHEMBL19514188 | 0.82 | — | — | |
| Bromide SCHEMBL16968721 | 0.79 | — | — | |
| Sebacic Acid SCHEMBL8435443 | 0.77 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL19026195 | 0.69 | KDM4E (0.35) | ALDH1A1 | |
| SCHEMBL25186232 | 0.67 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 | |
| Sebacic Acid SCHEMBL301600 | 0.67 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL21065467 | 0.67 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 | |
| Sebacic Acid SCHEMBL20500595 | 0.67 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671047-B2 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| EP-1517890-B1 | CATIONICALLY SUBSTITUTED DIPHENYL AZETIDINONES, METHOD FOR THEIR PRODUCTION, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1517890-A1 | CATIONICALLY SUBSTITUTED DIPHENYL AZETIDINONES, METHOD FOR THEIR PRODUCTION, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040077623-A1 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004000803-A1 | CATIONICALLY SUBSTITUTED DIPHENYL AZETIDINONES, METHOD FOR THEIR PRODUCTION, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077623-A1 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, DRD4, CYP2D6 | TSHR 3328/4885LMNA 1080/4885NFKB1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.